认知变化的时间进程和严重程度是Aβ阳性和阿波埃基因型在阿尔茨海默病中的函数
Casey R Vanderlip1, Craig E L Stark1
1From the Department of Neurobiology and Behavior, University of California, Irvine.
Neurology
|June 27, 2025
概括
由于粉样β (Aβ) 积累,APOE4基因携带者表现出更快的情节性记忆衰退,同卵性携带者经历了最显著的影响. 这种更高的易感性是特定于记忆,而不是其他认知功能.
科学领域:
- 神经遗传学 神经遗传学
- 认知神经科学 认知神经科学
- 阿尔茨海默氏症疾病研究研究
背景情况:
- APOE4是散发性阿尔茨海默病 (AD) 的主要遗传风险因素.
- 携带APOE4的患者表现出粉样β (Aβ) 沉积的增加和更快的认知衰退,特别是在情节性记忆中.
- 导致这种下降的确切机制 - - 增加的Aβ负担与增加的易感性 - - 尚不清楚.
研究的目的:
- 调查APOE4载体的加速情节性记忆下降是否是由Aβ沉积增加或对Aβ影响更容易受到影响引起的.
- 分析估计的Aβ持续时间对各个领域的认知轨迹的影响.
主要方法:
- 来自阿尔茨海默病神经成像计划 (ADNI) 队列的数据分析.
- 神经心理评估,Aβ PET成像和APOE基因定型.
- 使用样本代局部近似来评估认知轨迹,估计Aβ持续时间 (粉素阳性年).
主要成果:
- 携带APOE4的患者表现出与Aβ持续时间相关的更急剧的情节性记忆衰退.
- 同卵性APOE4载体 (4/4) 的衰减最明显,其次是异卵性 (3/4),然后是非载体 (3/3).
- 这种基因型依赖性下降是特定于情节性记忆的;其他认知领域不受影响. 情节性记忆是第一个在所有群体中表现出障碍的认知领域.
结论:
- 携带APOE4的携带者,特别是同胞体,对Aβ积累的认知性降低,主要影响情节性记忆.
- 根据APOE基因型,阿尔茨海默病的认知轨迹有很大差异.
- 需要进一步的研究来探索这些APOE4相关差异背后的独特的病理机制.
相关概念视频
Alzheimer's Disease: Overview
678
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
678
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265


